Skip to main content
NASDAQ:ZIOP

ZIOPHARM Oncology Competitors

$3.13
-0.04 (-1.26 %)
(As of 05/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.08
$3.19
50-Day Range
$2.98
$3.67
52-Week Range
$2.06
$5.95
Volume892,766 shs
Average Volume2.44 million shs
Market Capitalization$674.59 million
P/E RatioN/A
Dividend YieldN/A
Beta2.28

Competitors

ZIOPHARM Oncology (NASDAQ:ZIOP) Vs. AMGN, GILD, REGN, VRTX, BIIB, and ALXN

Should you be buying ZIOP stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to ZIOPHARM Oncology, including Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

ZIOPHARM Oncology (NASDAQ:ZIOP) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, profitability, valuation and risk.

Insider & Institutional Ownership

48.0% of ZIOPHARM Oncology shares are held by institutional investors. Comparatively, 75.2% of Amgen shares are held by institutional investors. 2.3% of ZIOPHARM Oncology shares are held by insiders. Comparatively, 0.4% of Amgen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares ZIOPHARM Oncology and Amgen's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ZIOPHARM Oncology$150,000.004,497.29$-117,800,000.00($0.34)-9.21
Amgen$23.36 billion6.21$7.84 billion$14.8217.03

Amgen has higher revenue and earnings than ZIOPHARM Oncology. ZIOPHARM Oncology is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for ZIOPHARM Oncology and Amgen, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ZIOPHARM Oncology03202.40
Amgen291402.48

ZIOPHARM Oncology currently has a consensus target price of $5.6250, indicating a potential upside of 79.71%. Amgen has a consensus target price of $255.8571, indicating a potential upside of 1.38%. Given ZIOPHARM Oncology's higher probable upside, research analysts plainly believe ZIOPHARM Oncology is more favorable than Amgen.

Risk and Volatility

ZIOPHARM Oncology has a beta of 2.28, indicating that its stock price is 128% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500.

Profitability

This table compares ZIOPHARM Oncology and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ZIOPHARM OncologyN/A-48.49%-43.53%
Amgen29.42%95.55%15.52%

Summary

Amgen beats ZIOPHARM Oncology on 10 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and ZIOPHARM Oncology (NASDAQ:ZIOP) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, dividends, earnings and risk.

Institutional & Insider Ownership

76.4% of Gilead Sciences shares are held by institutional investors. Comparatively, 48.0% of ZIOPHARM Oncology shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by company insiders. Comparatively, 2.3% of ZIOPHARM Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Gilead Sciences and ZIOPHARM Oncology, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences091202.57
ZIOPHARM Oncology03202.40

Gilead Sciences currently has a consensus price target of $100.5909, indicating a potential upside of 45.64%. ZIOPHARM Oncology has a consensus price target of $5.6250, indicating a potential upside of 79.71%. Given ZIOPHARM Oncology's higher probable upside, analysts clearly believe ZIOPHARM Oncology is more favorable than Gilead Sciences.

Profitability

This table compares Gilead Sciences and ZIOPHARM Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences5.48%37.77%12.76%
ZIOPHARM OncologyN/A-48.49%-43.53%

Volatility & Risk

Gilead Sciences has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, ZIOPHARM Oncology has a beta of 2.28, meaning that its stock price is 128% more volatile than the S&P 500.

Valuation & Earnings

This table compares Gilead Sciences and ZIOPHARM Oncology's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion3.86$5.39 billion$6.1411.25
ZIOPHARM Oncology$150,000.004,497.29$-117,800,000.00($0.34)-9.21

Gilead Sciences has higher revenue and earnings than ZIOPHARM Oncology. ZIOPHARM Oncology is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Gilead Sciences beats ZIOPHARM Oncology on 10 of the 14 factors compared between the two stocks.

ZIOPHARM Oncology (NASDAQ:ZIOP) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, earnings and profitability.

Profitability

This table compares ZIOPHARM Oncology and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ZIOPHARM OncologyN/A-48.49%-43.53%
Regeneron Pharmaceuticals38.28%28.97%20.11%

Earnings & Valuation

This table compares ZIOPHARM Oncology and Regeneron Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ZIOPHARM Oncology$150,000.004,497.29$-117,800,000.00($0.34)-9.21
Regeneron Pharmaceuticals$7.86 billion7.14$2.12 billion$21.4724.39

Regeneron Pharmaceuticals has higher revenue and earnings than ZIOPHARM Oncology. ZIOPHARM Oncology is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for ZIOPHARM Oncology and Regeneron Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ZIOPHARM Oncology03202.40
Regeneron Pharmaceuticals051402.74

ZIOPHARM Oncology presently has a consensus price target of $5.6250, indicating a potential upside of 79.71%. Regeneron Pharmaceuticals has a consensus price target of $656.3810, indicating a potential upside of 25.33%. Given ZIOPHARM Oncology's higher probable upside, analysts plainly believe ZIOPHARM Oncology is more favorable than Regeneron Pharmaceuticals.

Risk and Volatility

ZIOPHARM Oncology has a beta of 2.28, meaning that its stock price is 128% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500.

Institutional & Insider Ownership

48.0% of ZIOPHARM Oncology shares are owned by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. 2.3% of ZIOPHARM Oncology shares are owned by insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Regeneron Pharmaceuticals beats ZIOPHARM Oncology on 11 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and ZIOPHARM Oncology (NASDAQ:ZIOP) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

Earnings & Valuation

This table compares Vertex Pharmaceuticals and ZIOPHARM Oncology's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion13.45$1.18 billion$4.2950.43
ZIOPHARM Oncology$150,000.004,497.29$-117,800,000.00($0.34)-9.21

Vertex Pharmaceuticals has higher revenue and earnings than ZIOPHARM Oncology. ZIOPHARM Oncology is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Vertex Pharmaceuticals and ZIOPHARM Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals38.51%28.55%20.68%
ZIOPHARM OncologyN/A-48.49%-43.53%

Institutional and Insider Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 48.0% of ZIOPHARM Oncology shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Comparatively, 2.3% of ZIOPHARM Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Vertex Pharmaceuticals and ZIOPHARM Oncology, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals041512.85
ZIOPHARM Oncology03202.40

Vertex Pharmaceuticals currently has a consensus target price of $292.00, indicating a potential upside of 34.97%. ZIOPHARM Oncology has a consensus target price of $5.6250, indicating a potential upside of 79.71%. Given ZIOPHARM Oncology's higher possible upside, analysts clearly believe ZIOPHARM Oncology is more favorable than Vertex Pharmaceuticals.

Volatility & Risk

Vertex Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, ZIOPHARM Oncology has a beta of 2.28, indicating that its share price is 128% more volatile than the S&P 500.

Summary

Vertex Pharmaceuticals beats ZIOPHARM Oncology on 11 of the 15 factors compared between the two stocks.

ZIOPHARM Oncology (NASDAQ:ZIOP) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, valuation and earnings.

Earnings & Valuation

This table compares ZIOPHARM Oncology and Biogen's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ZIOPHARM Oncology$150,000.004,497.29$-117,800,000.00($0.34)-9.21
Biogen$14.38 billion2.94$5.89 billion$33.578.35

Biogen has higher revenue and earnings than ZIOPHARM Oncology. ZIOPHARM Oncology is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ZIOPHARM Oncology and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ZIOPHARM OncologyN/A-48.49%-43.53%
Biogen35.63%51.00%23.54%

Institutional & Insider Ownership

48.0% of ZIOPHARM Oncology shares are held by institutional investors. Comparatively, 83.5% of Biogen shares are held by institutional investors. 2.3% of ZIOPHARM Oncology shares are held by insiders. Comparatively, 0.5% of Biogen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations for ZIOPHARM Oncology and Biogen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ZIOPHARM Oncology03202.40
Biogen4141202.27

ZIOPHARM Oncology presently has a consensus price target of $5.6250, indicating a potential upside of 79.71%. Biogen has a consensus price target of $305.5714, indicating a potential upside of 8.98%. Given ZIOPHARM Oncology's stronger consensus rating and higher possible upside, analysts clearly believe ZIOPHARM Oncology is more favorable than Biogen.

Volatility & Risk

ZIOPHARM Oncology has a beta of 2.28, suggesting that its stock price is 128% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500.

Summary

Biogen beats ZIOPHARM Oncology on 9 of the 14 factors compared between the two stocks.

ZIOPHARM Oncology (NASDAQ:ZIOP) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, valuation and earnings.

Earnings & Valuation

This table compares ZIOPHARM Oncology and Alexion Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ZIOPHARM Oncology$150,000.004,497.29$-117,800,000.00($0.34)-9.21
Alexion Pharmaceuticals$4.99 billion7.74$2.40 billion$9.7417.94

Alexion Pharmaceuticals has higher revenue and earnings than ZIOPHARM Oncology. ZIOPHARM Oncology is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ZIOPHARM Oncology and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ZIOPHARM OncologyN/A-48.49%-43.53%
Alexion Pharmaceuticals16.32%23.16%14.76%

Volatility & Risk

ZIOPHARM Oncology has a beta of 2.28, suggesting that its stock price is 128% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.

Institutional & Insider Ownership

48.0% of ZIOPHARM Oncology shares are held by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are held by institutional investors. 2.3% of ZIOPHARM Oncology shares are held by insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations for ZIOPHARM Oncology and Alexion Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ZIOPHARM Oncology03202.40
Alexion Pharmaceuticals015402.21

ZIOPHARM Oncology presently has a consensus price target of $5.6250, indicating a potential upside of 79.71%. Alexion Pharmaceuticals has a consensus price target of $159.3158, indicating a potential downside of 8.83%. Given ZIOPHARM Oncology's stronger consensus rating and higher possible upside, analysts clearly believe ZIOPHARM Oncology is more favorable than Alexion Pharmaceuticals.

Summary

Alexion Pharmaceuticals beats ZIOPHARM Oncology on 10 of the 14 factors compared between the two stocks.


ZIOPHARM Oncology Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.3$252.38-0.4%$145.01 billion$23.36 billion20.35Ex-Dividend
Analyst Report
Gilead Sciences logo
GILD
Gilead Sciences
2.8$69.07-0.8%$86.63 billion$22.45 billion71.21
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$523.73-1.4%$56.11 billion$7.86 billion19.14
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.0$216.35-0.3%$56.01 billion$4.16 billion27.32
Biogen logo
BIIB
Biogen
1.5$280.40-0.1%$42.22 billion$14.38 billion9.28
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$174.75-0.7%$38.62 billion$4.99 billion40.83
Seagen logo
SGEN
Seagen
1.7$147.98-0.3%$26.85 billion$916.71 million58.26Analyst Report
Incyte logo
INCY
Incyte
1.6$82.27-0.4%$18.09 billion$2.16 billion-52.40
Exact Sciences logo
EXAS
Exact Sciences
2.0$94.67-2.2%$16.24 billion$876.29 million-42.84Analyst Revision
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.6$135.89-0.1%$15.97 billion$219.75 million-17.36Insider Selling
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$77.34-0.5%$14.13 billion$1.70 billion17.70
Novavax logo
NVAX
Novavax
1.8$140.16-6.0%$10.39 billion$18.66 million-26.85Earnings Announcement
Analyst Revision
Repligen logo
RGEN
Repligen
1.9$165.87-3.7%$9.11 billion$270.24 million202.28
United Therapeutics logo
UTHR
United Therapeutics
1.5$198.29-0.2%$8.88 billion$1.45 billion18.76
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$93.08-1.6%$8.80 billion$788.10 million100.09
Exelixis logo
EXEL
Exelixis
1.9$25.24-1.3%$7.91 billion$967.78 million52.58Insider Selling
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.7$42.42-1.4%$6.04 billion$195.99 million265.13Earnings Announcement
Analyst Report
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$37.32-2.5%$5.26 billion$1.12 billion77.75Analyst Report
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$60.89-0.9%$3.70 billion$806.43 million-8.62
Alkermes logo
ALKS
Alkermes
1.2$22.08-0.8%$3.54 billion$1.17 billion-48.00
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$60.29-2.8%$3.23 billion$1.11 billion19.39
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.3$14.38-10.7%$2.56 billion$48.83 million-18.92
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.4$9.23-2.8%$2.46 billion$182.24 million-8.03Analyst Revision
OPKO Health logo
OPK
OPKO Health
1.9$3.61-2.5%$2.42 billion$901.90 million-20.05
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$134.00-0.5%$2.22 billionN/A-12.10Analyst Report
Analyst Revision
News Coverage
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$125.17-3.5%$2.08 billion$120.28 million-126.43
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$27.03-1.3%$2.08 billion$638.60 million-10.40
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$11.85-1.4%$1.91 billion$428.41 million17.17
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$10.89-0.4%$1.57 billion$102.43 million-18.15
Curis logo
CRIS
Curis
1.1$15.05-9.8%$1.38 billion$10 million-18.35Earnings Announcement
Analyst Revision
Gap Down
ImmunoGen logo
IMGN
ImmunoGen
1.5$6.71-0.6%$1.34 billion$82.27 million-16.37Earnings Announcement
Innoviva logo
INVA
Innoviva
1.1$12.77-0.8%$1.29 billion$261.02 million6.52
Codexis logo
CDXS
Codexis
1.5$18.18-0.6%$1.17 billion$68.46 million-51.94
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$27.38-1.1%$1.08 billion$3.57 million-12.28
MannKind logo
MNKD
MannKind
1.4$4.23-1.9%$1.05 billion$63.04 million-20.14Earnings Announcement
Analyst Revision
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$18.58-0.4%$1.03 billion$227.19 million51.61
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$7.76-0.5%$889.20 million$35.22 million-5.66Gap Down
Agenus logo
AGEN
Agenus
1.6$3.26-0.9%$725.16 million$150.05 million-2.99
ChemoCentryx logo
CCXI
ChemoCentryx
1.7$9.89-5.6%$689.83 million$36.13 million-14.76
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.3$18.57-1.2%$674.61 millionN/A0.00Analyst Report
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.68-0.8%$626.20 million$59.29 million-24.53
Clovis Oncology logo
CLVS
Clovis Oncology
1.2$5.87-0.0%$613.80 million$143.01 million-1.12
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$4.23-2.4%$610.76 million$322.07 million-4.03Analyst Revision
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$17.26-5.2%$572.38 million$252 million-1.76
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.44-1.2%$535.65 million$109.33 million-2.53Earnings Announcement
Verastem logo
VSTM
Verastem
1.5$2.94-0.0%$505.44 million$17.46 million-2.09Earnings Announcement
Molecular Templates logo
MTEM
Molecular Templates
2.0$8.29-5.2%$464.97 million$22.27 million-4.06Earnings Announcement
Geron logo
GERN
Geron
1.4$1.43-0.0%$455.55 million$460,000.00-4.09Analyst Upgrade
Analyst Revision
XOMA logo
XOMA
XOMA
1.5$30.75-2.7%$346.55 million$18.37 million-27.70Analyst Revision
Fortress Biotech logo
FBIO
Fortress Biotech
1.6$3.54-4.0%$344.28 million$36.63 million-4.16News Coverage
This page was last updated on 5/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.